About Collage Venture Partners
Collage Venture Partners is a venture capital firm founded in 2019. It is primarily based out of Miami Beach, United States. As of Aug 2024, Collage Venture Partners has invested in 22 companies. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and Enterprise Applications. Most recently it participated in the $***** Series A round of Retension Pharmaceuticals Overall, Collage Venture Partners portfolio has seen 10 IPOs and 1 acquisition including key companies like CareDx, Atea and Axsome Therapeutics. Collage Venture Partners has team of 8 people including 2 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A
Portfolio Acquisitions
Portfolio Soonicorns
Collage Venture Partners' List of Top Investments
Collage Venture Partners has a portfolio of 22 companies. Their most notable investmentis in Bond BiosciencesTheir portfolio spans across and United States. They have invested in Life Sciences, HealthTech, Enterprise Applications and 3 other sectors, across stages such as Series A stage. Here is the list of top investments by Collage Venture Partners:
1. CareDx
Developer of medical solutions for transplant patients. It has developed precision medicine solutions that offer products, testing services, and digital healthcare solutions along with the pre-and post-transplant patient journey. It provides AlloSure products for a kidney transplant. It is a non-invasive donor-derived cell-free DNA test for identifying kidney injury. It can determine active rejection, enabling better management of your kidney transplant patients. Other products include heart transplants, lab products, remotrac, and others.
Key facts about CareDx
- Founded Year: 1998
- Location: Brisbane (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $138M
- Employee Count: 856 as on Jul 31, 2026
- Investors: Intel, Integral Capital Partners and 24 Others
- Latest Funding Round: Conventional Debt, Mar 01, 2018, $*****
- Highlight: Public
_1579497693661.png?format=webp&height=120&width=120){kind=logo}
2. Atea
Developer of therapeutics for viral diseases. It helps users in the treatment of infections caused by RNA and DNA viruses. It also gives solutions for various diseases like Hepatitis C, Dengue, Respiratory Syncytial Virus (RSV), Hepatitis B, and many more.
Key facts about Atea
- Founded Year: 2014
- Location: Boston (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2021
- Stage: Public
- Total Funding till date: $293M
- Employee Count: 58 as on Jul 31, 2026
- Investors: HTIF, Bain Capital Life Sciences and 18 Others
- Latest Funding Round: Post IPO, Jun 13, 2023, $*****
- Highlight: Public
Developer of therapeutics for the management of CNS disorders. The company's pipeline includes two late-stage product candidates, AXS-05 (bupropion and dextromethorphan) and AXS-02 (disodium zoledronate tetrahydrate) for multiple indications including treatment-resistant depression, agitation in Alzheimer's disease, complex regional pain syndrome (CRPS), Knee Osteo Arthritis related bone marrow lesions (BMLs) and chronic low back pain.
Key facts about Axsome Therapeutics
- Founded Year: 2012
- Location: New York City (United States)
- Annual Revenue: $500M - $1B as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $8.7M
- Employee Count: 1,203 as on Jul 31, 2026
- Investors: Venrock, Collage Venture Partners and 1 Other
- Latest Funding Round: Post IPO, Jan 07, 2019, $*****
- Highlight: Public
4. Rezolute
Developing transformative therapies for rare diseases, focusing on hyperinsulinism (HI). The company is a late-stage biopharmaceutical company dedicated to addressing serious unmet needs in rare diseases. It is focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Their antibody therapy, ersodetug, is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital hyperinsulinism (cHI) and tumor HI. The company is committed to developing medicines and working with partners to fight hyperinsulinism in all its forms. They are enrolling Phase III sunRIZE trial in the study of congenital hyperinsulinism. The company is focused on drug development for patients with rare diseases in multiple therapeutic areas.
Key facts about Rezolute
- Founded Year: 2012
- Location: Denver (United States)
- Stage: Public
- Employee Count: 76 as on Jul 31, 2026
- Investors: BVF Partners, Lincoln Park Capital and 8 Others
- Latest Funding Round: Post IPO, Oct 09, 2020, $*****
- Highlight: Public
Developer of MRI-guided stereotactic system for neurological interventions. It specializes in precise navigation systems for brain and spine procedures, enabling device, cell, and gene therapies with real-time imaging and minimally invasive techniques.
Key facts about ClearPoint Neuro
- Founded Year: 1998
- Location: Irvine (United States)
- Annual Revenue: $10M - $50M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $33.7M
- Employee Count: 156 as on Jul 31, 2026
- Investors: Oberland Capital, Collage Venture Partners and 5 Others
- Latest Funding Round: Post IPO, May 19, 2025, $*****
- Highlight: Public
Collage Venture Partners' Year-on-Year Investment Trends
Collage Venture Partners has invested in 22 companies over the last 4 years, with an average of 0 new investment annually in the last 3 years. Its most recent first time investment was in Retension Pharmaceuticals.Collage Venture Partners' Investments by Stage
Collage Venture Partners has made 2 investments in Series A stage with an average round size of $10.4M.Collage Venture Partners' Investments by Sector
Collage Venture Partners has a portfolio focused on Life Sciences. Notably, it has invested in 19 Enterprise (B2B) companies, 19 Tech companies, 3 Software companies and 2 companies focusing on Tech hardware.Collage Venture Partners' Investments by Geography
Collage Venture Partners has made most investments in United States (2).Collage Venture Partners' recent investments
Collage Venture Partners has not made any investment in 2026 so far.Here are the most recent investments by Collage Venture Partners:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Aug 21, 2024 | United States | Series A | 7133 | - | |
Jan 05, 2022 | United States | Series A | 7308 | - |
IPOs and Publicly Listed companies in Collage Venture Partners' Portfolio
10 of Collage Venture Partners' portfolio companies have become public. Atea got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Oct 2020 and Atreca got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $455M.Here are Collage Venture Partners' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Oct 30, 2020 | - | - | 5332 | |
Jun 20, 2019 | - | - | 7903 | |
Sep 22, 2017 | - | - | 3595 | |
Aug 15, 2016 | - | - | 5398 | |
Nov 19, 2015 | - | - | 7113 |
_1579497693661.png?devicePixelRatio=2&height=20&width=20){kind=logo}
Acquired companies in Collage Venture Partners' Portfolio
1 company from Collage Venture Partners' portfolio has been acquired. The most recent acquisition was Applied Therapeutics in Dec 2025 by Cycle Pharma for $*****.Here are Collage Venture Partners' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Dec 11, 2025 | - | - | 7187 |
Team profile of Collage Venture Partners
Collage Venture Partners has a team of 8 members including 2 Partners, 1 Venture Partner and 2 Principals located in United States. Collage Venture Partners' team does not sit on the board of any company as of now.Here is a list of all team members in Collage Venture Partners:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | New York City | - | ||
Partner | Miami Beach | - | ||
Venture Partner | Miami | - | ||
Principal | Miami Beach | - | - | |
Principal | United States | - |
Co-investors of Collage Venture Partners
Over the past 4 years, 2 investors have co-invested in Collage Venture Partners's portfolio companies. This includes only funds.
- Invested before Collage Venture Partners: BioGenerator and HHS have invested in rounds before Collage Venture Partners. There is 1 company where BioGenerator has invested before Collage Venture Partners and 1 company where HHS has invested before Collage Venture Partners.
Recent News related to Collage Venture Partners
•
